Ovid Therapeutics - OVID Stock Forecast, Price & News

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ovid Therapeutics in the last twelve months. There are currently 2 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" OVID shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in OVID, but not buy additional shares or sell existing shares.
View OVID analyst ratings or view top-rated stocks.

2 analysts have issued 1-year price targets for Ovid Therapeutics' shares. Their OVID stock forecasts range from $2.40 to $2.40. On average, they predict the company's stock price to reach $2.40 in the next year. This suggests a possible upside of 8.6% from the stock's current price.
View analysts price targets for OVID or view top-rated stocks among Wall Street analysts.

Ovid Therapeutics' stock was trading at $3.21 at the beginning of 2022. Since then, OVID stock has decreased by 31.2% and is now trading at $2.21.
View the best growth stocks for 2022 here.

Ovid Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, August 15th 2022.
View our OVID earnings forecast.

Ovid Therapeutics Inc. (NASDAQ:OVID) posted its quarterly earnings results on Tuesday, May, 10th. The company reported ($0.23) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.17 by $1.40. The business earned $1.45 million during the quarter.

Based on aggregate information from My MarketBeat watchlists, some companies that other Ovid Therapeutics investors own include Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), VBI Vaccines (VBIV), Allena Pharmaceuticals (ALNA), Corbus Pharmaceuticals (CRBP), SCYNEXIS (SCYX), Enphase Energy (ENPH), Gilead Sciences (GILD) and Novavax (NVAX).

(OVID) raised $80 million in an initial public offering (IPO) on Friday, May 5th 2017. The company issued 5,000,000 shares at $15.00-$17.00 per share. Citigroup and Cowen and Company acted as the underwriters for the IPO and William Blair and JMP Securities were co-managers.

Ovid Therapeutics trades on the NASDAQ under the ticker symbol "OVID."

Ovid Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Russell Investments Group Ltd. (0.38%), Walker Asset Management LLC (0.06%), Walker Asset Management LLC (0.06%), Connor Clark & Lunn Investment Management Ltd. (0.05%) and Assenagon Asset Management S.A. (0.04%). Insiders that own company stock include Amit Rakhit, Jeremy M Levin and Pharmaceutical Co Ltd Takeda.
View institutional ownership trends.

Shares of OVID stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of OVID stock can currently be purchased for approximately $2.21.

Ovid Therapeutics (NASDAQ:OVID) has a market capitalization of $155.62 million and generates $208.38 million in revenue each year. The company earns $122.83 million in net income (profit) each year or ($1.01) on an earnings per share basis.

Ovid Therapeutics employs 57 workers across the globe.

Ovid Therapeutics' mailing address is 1460 Broadway Suite 15044, New York NY, 10036. The official website for the company is www.ovidrx.com. The company can be reached via phone at (646) 661-7661 or via email at investors@ovidrx.com.